Preclinical models of non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 68, Issue 2, 2018, Pages 230-237

  Santhekadur, Prasanna K ^a   Kumar, Divya P ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; Mouse models; NAFLD activity score; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Preclinical models; Transcriptome

Indexed keywords

CHOLESTEROL; CHOLIC ACID; CHOLINE; FRUCTOSE; LEPTIN; LEPTIN RECEPTOR; METHIONINE; STREPTOZOCIN;

ALSTROM SYNDROME; CHOLESTEROL DIET; CLINICAL EVALUATION; DIET SUPPLEMENTATION; DIETARY INTAKE; GENETIC ANALYSIS; GENETIC ENGINEERING; HUMAN; IRON INTAKE; LEPTIN DEFICIENCY; LEPTIN RECEPTOR DEFICIENCY; LIPID DIET; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORCINE MODEL; PRIORITY JOURNAL; REVIEW; VITAMIN DEFICIENCY; ANIMAL; DISEASE EXACERBATION; DISEASE MODEL; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85038928790     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.10.031     Document Type: Review

References (73)

1. Sanyal, A.J., Neuschwander-Tetri, B.A., Tonascia, J., End points must be clinically meaningful for drug development in nonalcoholic fatty liver disease. Gastroenterology 150 (2016), 11–13.
2. Wattacheril, J., Chalasani, N., Non-alcoholic fatty liver disease (NAFLD): Is it really a serious condition?. Hepatology 56 (2012), 1580–1584.
3. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
4. Ahmed, M.H., Husain, N.E., Almobarak, A.O., Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?. J Family Med Prim Care 4 (2015), 45–52.
5. Lai, M., Chandrasekera, P.C., Barnard, N.D., You are what you eat, or are you? The challenges of translating high-fat-fed rodents to human obesity and diabetes. Nutr Diabetes, 8, 2014, e135.
6. Bakiri, L., Wagner, E.F., Mouse models for liver cancer. Mol Oncol 7 (2013), 206–223.
7. Asgharpour, A., Cazanave, S.C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B.A., et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 65 (2016), 579–588.
8. Gao, B., Xu, M.J., Bertola, A., Wang, H., Zhou, Z., Liangpunsakul, S., Animal models of alcoholic liver disease: pathogenesis and clinical relevance. Gene Exp 17 (2017), 173–186.
9. Zivkovic, A.M., German, J.B., Sanyal, A.J., Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 86 (2007), 285–300.
10. Clapper, J.R., Hendricks, M.D., Gu, G., Wittmer, C., Dolman, C.S., Herich, J., et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 305 (2013), G483–G495.
11. Ibrahim, S.H., Hirsova, P., Malhi, H., Gores, G.J., Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame. Dig Dis Sci 61 (2016), 1325–1336.
12. Fan, J.G., Cao, H.X., Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 28 (2013), 81–87.
13. Sahai, A., Malladi, P., Melin-Aldana, H., Green, R.M., Whitington, P.F., Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 287 (2004), G264–G273.
14. Weltman, M.D., Farrell, G.C., Liddle, C., Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111 (1996), 1645–1653.
15. Machado, M.V., Michelotti, G.A., Xie, G., Almeida Pereira, T., Boursier, J., Bohnic, B., et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One, 10, 2015, e0127991.
16. Rinella, M.E., Green, R.M., The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40 (2004), 47–51.
17. Rinella, M.E., Elias, M.S., Smolak, R.R., Fu, T., Borensztajn, J., Green, R.M., Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49 (2008), 1068–1076.
18. Pierce, A.A., Pickens, M.K., Siao, K., Grenert, J.P., Maher, J.J., Differential hepatotoxicity of dietary and DNL-derived palmitate in the methionine-choline-deficient model of steatohepatitis. BMC Gastroenterol, 24, 2015, 72.
19. Nakae, D., Yoshiji, H., Maruyama, H., Kinugasa, T., Denda, A., Konishi, Y., Production of both 8-hydroxydeoxyguanosine in liver DNA and gamma-glutamyltransferase-positive hepatocellular lesions in rats given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 81 (1990), 1081–1084.
20. Nakae, D., Yoshiji, H., Mizumoto, Y., et al. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 52 (1992), 5042–5045.
21. Sakaida, I., Kubota, M., Kayano, K., Takenaka, K., Mori, K., Okita, K., Prevention of fibrosis reduces enzyme-altered lesions in the rat liver. Carcinogenesis 15 (1994), 2201–2206.
22. Denda, A., Kitayama, W., Kishida, H., et al. Expression of inducible nitric oxide (NO) synthase but not prevention by its gene ablation of hepatocarcinogenesis with fibrosis caused by a choline-deficient, l-amino acid-defined diet in rats and mice. Nitric Oxide 16 (2007), 164–176.
23. Matsumoto, M., Hada, N., Sakamaki, Y., Uno, A., Shiga, T., Tanaka, C., et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol 94 (2013), 93–103.
24. Kamada, Y., Matsumoto, H., Tamura, S., et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 47 (2007), 556–564.
25. Denda, A., Kitayama, W., Kishida, H., et al. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 93 (2002), 125–132.
26. Kodama, Y., Kisseleva, T., Iwaisako, K., et al. C-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137 (2009), 1467–1477.
27. Matsuzawa, N., Takamura, T., Kurita, S., Misu, H., Ota, T., Ando, H., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46 (2007), 1392–1403.
28. Zheng, S., Hoos, L., Cook, J., et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584 (2008), 118–124.
29. Subramanian, S., Goodspeed, L., Wang, S., et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res 52 (2011), 1626–1635.
30. Savard, C., Tartaglione, E.V., Kuver, R., et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 57 (2013), 81–92.
31. Lau, J.K., Zhang, X., Yu, J., Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol 241 (2017), 36–44.
32. Vergnes, L., Phan, J., Strauss, M., Tafuri, S., Reue, K., Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem 278 (2003), 42774–42784.
33. Takahashi, Y., Soejima, Y., Fukusato, T., Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18 (2012), 2300–2308.
34. Nakamura, A., Terauchi, Y., Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci 14 (2013), 21240–21257.
35. Haluzik, M., Colombo, C., Gavrilova, O., Chua, S., Wolf, N., Chen, M., et al. Genetic background (C57BL/6J vs. FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 145 (2004), 3258–3264.
36. Kohli, R., Kirby, M., Xanthakos, S.A., et al. High-fructose, medium chain trans-fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52 (2010), 934–944.
37. Abdelmalek, M.F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R.J., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1961–1971.
38. Charlton, M., Krishnan, A., Viker, K., Sanderson, S., Cazanave, S., McConico, A., et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301 (2011), G825–G834.
39. Lee, J.S., Jun, D.W., Kim, E.K., Jeon, H.J., Nam, H.H., Saeed, W.K., Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models. Sci World J, 2015, 2015, 306326.
40. Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 46 (2013), 141–152.
41. Radosavljević T., Mladenović D., Vucević D., Vukićević R.J., et al. The role of oxidative/nitrosative stress in pathogenesis of paracetamol-induced toxic hepatitis. Med Pregl 63 (2010), 827–832.
42. Sadi, G., Baloğlu, M.C., Pektaş M.B., Differential gene expression in liver tissues of streptozotocin-induced diabetic rats in response to resveratrol treatment. PLoS One, 10, 2015, e0124968.
43. Brown, G.T., Kleiner, D.E., Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65 (2016), 1080–1086.
44. Malhi, H., Gores, G.J., Cellular and molecular mechanisms of liver injury. Gastroenterology 134 (2008), 1641–1654.
45. Andrisani, O.M., Studach, L., Merle, P., Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 21 (2011), 4–9.
46. Lee, L., Alloosh, M., Saxena, R., Van Alstine, W., Watkins, B.A., Klaunig, J.E., et al. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology 50 (2009), 56–67.
47. Lindström, P., The physiology of obese-hyperglycemic mice [ob/ob mice]. Sci World J 29 (2007), 666–685.
48. Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 16 (2012), 44–54.
49. Javor, E.D., Ghany, M.G., Cochran, E.K., Oral, E.A., DePaoli, A.M., Premkumar, A., et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41 (2005), 753–760.
50. Safar Zadeh, E., Lungu, A.O., Cochran, E.K., Brown, R.J., Ghany, M.G., Heller, T., et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 59 (2013), 131–137.
51. Polyzos, S.A., Kountouras, J., Mantzoros, C.S., Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64 (2015), 60–78.
52. Hummel, K.P., Dickie, M.M., Coleman, D.L., Diabetes, a new mutation in the mouse. Science 153 (1966), 1127–1128.
53. Trak-Smayra, V., Paradis, V., Massart, J., Nasser, S., Jebara, V., Fromenty, B., Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol 92 (2011), 413–421.
54. Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R.M., et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: Role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287 (2004), G1035–G1043.
55. Handa, P., Morgan-Stevenson, V., Maliken, B.D., et al. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. Am J Physiol Gastrointest Liver Physiol 310 (2016), G117–G127.
56. Valenti, L., Fracanzani, A.L., Dongiovanni, P., Bugianesi, E., Marchesini, G., Manzini, P., et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 102 (2007), 1251–1258.
57. Laurence, P., Vanessa, L., Geoffrey, F., Isabelle, L., Role of ciliary dysfunction in a new model of obesity and non-alcoholic steatohepatitis: the foz/foz mice. Arch Public Health, 72, 2014, O7.
58. Heydet, D., Chen, L.X., Larter, C.Z., Inglis, C., Silverman, M.A., Farrell, G.C., et al. A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev Neurobiol 73 (2012), 1–13.
59. Arsov, T., Larter, C.Z., Nolan, C.J., Petrovsky, N., Goodnow, C.C., Teoh, N.C., et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 342 (2006), 1152–1159.
60. Bell-Anderson, K.S., Aouad, L., Williams, H., et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism infat Aussie mice. Int J Obes (Lond) 35 (2011), 1539–1548.
61. Shimomura, I., Hammer, R.E., Richardson, J.A., Ikemoto, S., Bashmakov, Y., Goldstein, J.L., et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear srebp-1c in adipose tissue: Model for congenital generalized lipodystrophy. Genes Dev 12 (1998), 3182–3194.
62. Okumura, K., Ikejima, K., Kon, K., Abe, W., Yamashina, S., Enomoto, N., et al. Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic kk-a(y) mice. Hepatol Res 36 (2006), 217–228.
63. Costet, P., Legendre, C., More, J., Edgar, A., Galtier, P., Pineau, T., Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273 (1998), 29577–29585.
64. Martinez-Chantar, M.L., Corrales, F.J., Martinez-Cruz, L.A., Garcia-Trevijano, E.R., Huang, Z.Z., Chen, L., et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1a. FASEB J 16 (2002), 1292–1294.
65. Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., et al. Hepatocyte-specific pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113 (2004), 1774–1783.
66. Fan, C.Y., Pan, J., Usuda, N., Yeldandi, A.V., Rao, M.S., Reddy, J.K., Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-coa oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273 (1998), 15639–15645.
67. Morinaga, H., Mayoral, R., Heinrichsdorff, J., et al. Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. Diabetes 64 (2015), 1120–1130.
68. Gomez Perdiguero, E., Klapproth, K., Schulz, C., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518 (2015), 547–551.
69. Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., Seki, E., Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302 (2012), G1310–G1321.
70. Wenfeng, Z., Yakun, W., Di, M., Jianping, G., Chuanxin, W., Chun, H., Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Ann Hepatol 13 (2014), 489–495.
71. Shi, C., Pamer, E.G., Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11 (2011), 762–774.
72. Csak, T., Velayudham, A., Hritz, I., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 300 (2011), G433–G441.
73. Hosoi, T., Yokoyama, S., Matsuo, S., Akira, S., Ozawa, K., Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of diabetes in mice. PLoS One, 5, 2010, e12537.